The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I study of HM781-36B, a novel pan-HER inhibitor, in patients (pts) with advanced solid tumors.
Tae Min Kim
No relevant relationships to disclose
Keun-Wook Lee
No relevant relationships to disclose
Do-Youn Oh
Research Funding - Preclinical research of HMB78136B
Jong-Seok Lee
No relevant relationships to disclose
Seock-Ah Im
Consultant or Advisory Role - Hanmi (U)
Dong-Wan Kim
No relevant relationships to disclose
Sae-Won Han
No relevant relationships to disclose
Yu Jung Kim
No relevant relationships to disclose
Tae-You Kim
Research Funding - Hanmi
Jee Hyun Kim
Research Funding - Hanmi
Kyung-Mi Park
Employment or Leadership Position - Clinical research director
Jeewoong Son
Employment or Leadership Position - Clinical research director
Yung-Jue Bang
Consultant or Advisory Role - Preclinical research
Honoraria - Preclinical research
Research Funding - Preclinical research